Research-Based Pharma Urges Redress From Negative Impact Of EU SPC Waiver

The research-based pharmaceutical industry has issued a severe warning that the European Parliament's overwhelming support for IP-related changes that will allow manufacturing of generics and biosimilars during the term of supplementary protection certificates will hit innovation. Some of industry's concerns may be justified, a patent attorney explains.